Register for an event to:
- Understand the ongoing challenges for patients with PNH and the evolution of management
- Dive into the efficacy and safety data for FABHALTA in both C5i-experienced (eculizumab and ravulizumab) and complement inhibitor–naive adults with PNH
- Hear perspectives on patients who may be appropriate for FABHALTA
- Learn about the process for getting patients started
Hear what PNH medical experts have to say about FABHALTA
Who Is an Appropriate Patient for FABHALTA?
PNH medical experts share their experience treating patients with FABHALTA, empowering you to make informed decisions in your practice.
Discover How FABHALTA May Benefit Adult Patients With PNH
Hear from medical experts who actively treat and manage PNH in their clinical practices.
The Clinical Data Behind FABHALTA
Hear medical experts discuss the clinical data for FABHALTA and what this can mean for adult patients with PNH.
Medical Experts Discuss the Use of FABHALTA
Hear from medical experts as they discuss their approach to treating PNH.
Your Questions About FABHALTA Answered
Hear a panel of experts discuss frequently asked questions about FABHALTA.
The medical experts featured in the above videos were compensated for their time by Novartis Pharmaceuticals Corporation.
Read the latest clinical perspectives on PNH
Discover FABHALTA, the First and Only FDA-Approved Oral Monotherapy for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH medical experts, Dr. Lawrence Rice, and Dr. Ilene Weitz discuss PNH and the clinical data for FABHALTA.
Exploring the Switch to FABHALTA for Adult Patients With PNH
Dr. Majerus discusses the clinical data of FABHALTA and provides key considerations when switching patients who were previously on a C5i (eculizumab or ravulizumab) to FABHALTA. She also shares best practices on monitoring patients taking FABHALTA.
The medical experts featured in this newsletter were compensated for their time by Novartis Pharmaceuticals Corporation.